Search results
Results from the WOW.Com Content Network
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron.
Toggle Reuptake inhibitors subsection. 2.1 Dopamine transporter (DAT) inhibitors. 2.2 Vesicular monoamine transporter ... Dopamine. This is a list of dopaminergic drugs.
Serotonin–norepinephrine–dopamine reuptake inhibitors (57 P) Pages in category "Dopamine reuptake inhibitors" The following 99 pages are in this category, out of 99 total.
At present, only one norepinephrine-dopamine reuptake inhibitor is approved by the FDA to treat depression: bupropion (Wellbutrin). It boosts the concentration of norepinephrine and dopamine ...
Toggle Serotonin–dopamine reuptake inhibitor (SDRIs) subsection 3.1 Discontinued/withdrawn 4 Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs)
The skeletal structure of norepinephrine The skeletal structure of dopamine. A norepinephrine–dopamine reuptake inhibitor (NDRI) is a drug used for the treatment of clinical depression, attention deficit hyperactivity disorder (ADHD), narcolepsy, and the management of Parkinson's disease.
These medications are called norepinephrine and dopamine reuptake inhibitors (or NDRIs). NDRIs like Wellbutrin prevent your neurons from reabsorbing norepinephrine and dopamine. As a result, more ...
In addition, the augmentation of a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor with lisdexamfetamine, a norepinephrine–dopamine releasing agent, recently failed to separate from placebo in phase III clinical trials of individuals with treatment-resistant depression, and clinical development was ...